Conflict of interest
Non-segmental vitiligo and psoriasis comorbidity – a case-control study in Italian patients
Article first published online: 26 FEB 2013
© 2013 The Authors Journal of the European Academy of Dermatology and Venereology © 2013 European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology
Volume 28, Issue 4, pages 433–437, April 2014
How to Cite
Arunachalam, M., Dragoni, F., Colucci, R., Berti, S., Crocetti, E., Galeone, M., Conti, R. and Moretti, S. (2014), Non-segmental vitiligo and psoriasis comorbidity – a case-control study in Italian patients. Journal of the European Academy of Dermatology and Venereology, 28: 433–437. doi: 10.1111/jdv.12117
The authors have no conflict of interest to declare.
There were no funding sources utilized for this work.
- Issue published online: 18 MAR 2014
- Article first published online: 26 FEB 2013
- Manuscript Accepted: 21 JAN 2013
- Manuscript Revised: 28 DEC 2012
- Manuscript Received: 27 OCT 2012
A recent systematic evaluation of vitiligo and psoriasis comorbidity has not yet been reported in a large series of patients with vitiligo.
To investigate the practical/clinical implications in subjects with both vitiligo and psoriasis compared to those with vitiligo alone.
This was a case-control study on 463 vitiligo patients in our clinic from March 2008 to April 2011. Medical assessment was performed by dermatologists using the modified Vitiligo European Task Force form.
In an univariate analysis, inflammation/pruritus [odds ratio (OR) 2.42, P = 0.03], use of drugs that can induce psoriasis (OR 2.74, P = 0.01), a family history (FH) of psoriasis (OR 2.87, P = 0.02), cardiovascular disease (OR 5.70, P = 0.001), hypertension (OR 4.7, P = 0.006) and type 2 diabetes mellitus (OR 3.87, P = 0.004), were significantly correlated with patients exhibiting vitiligo and psoriasis comorbidity. A trend was found in personal history of cardiovascular disease in patients with both diseases (OR 2.99, P = 0.07). FH of vitiligo was significantly associated with patients having only vitiligo (OR 0.35, P = 0.05). Multivariate analysis demonstrated that inflammation/pruritus in vitiligo macules (OR 2.56, P = 0.047) and a FH of cardiovascular disease (OR 4.07, P = 0.02) were the most significant predictors of patients having both psoriasis and vitiligo, while the presence of organ-specific autoantibodies (OR 0.24, P = 0.007) was significantly associated with patients having only vitiligo.
The presence of vitiligo and even mild psoriasis is significantly correlated with a family history of cardiovascular disease, a factor that requires greater attention and follow-up with respect to that necessary for vitiligo patients.